---
title: "FRONTAGE to Be Privatized: CRO Leader Tigermed Exits with Cash to Streamline Operations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305009978.md"
description: "Tigermed announced its participation in the privatization of its subsidiary, FRONTAGE, and the sale of its controlling stake to divest overseas laboratory operations. The transaction will be conducted through a new platform, SanRex. Upon FRONTAGE's delisting, it will be split into three parts: domestic operations retained by Tigermed (valued at $205.5 million), core overseas operations sold to CRL ($470 million), and the remainder distributed to the founding team. This move aims to optimize resource allocation and focus on the core clinical CRO business. While this may create a revenue gap, it will generate cash consideration and investment income"
datetime: "2026-11-10T12:10:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305009978.md)
  - [en](https://longbridge.com/en/news/305009978.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305009978.md)
generator: "portal-rs"
---

# FRONTAGE to Be Privatized: CRO Leader Tigermed Exits with Cash to Streamline Operations

After 12 years under its umbrella, the "marriage" between **Tigermed (300347.SZ)** and **FRONTAGE (01521.HK)** may be nearing its end.

Recently, Tigermed announced that it would participate in the privatization of its subsidiary, FRONTAGE, while selling its controlling interest and divesting FRONTAGE's overseas laboratory business. If successfully completed, the transaction will bring Tigermed cash consideration and a substantial amount of investment income on its books. However, FRONTAGE will no longer be included in the company's consolidated financial statements, which may result in a revenue gap compared to previous periods.

**"Privatization + Spin-off" Proceeding Simultaneously**

According to Tigermed's announcement on November 10, the transaction consists of two parts: privatization and a spin-off. In simple terms, Tigermed, together with CRL, a global leader in preclinical CRO services, and Li Song, the founder of FRONTAGE, will establish a new platform, SanRex, to first delist FRONTAGE from the Hong Kong Stock Exchange. Subsequently, FRONTAGE will be split into three parts: the overseas portion will be sold to CRL and Li Song; Tigermed will retain only the domestic laboratory business and receive a sum of cash, ceasing to consolidate FRONTAGE's entire operations in the future.

The portion retained by Tigermed is valued at $205.5 million, primarily comprising FRONTAGE's domestic business, including the Shanghai laboratory and Guanhe Medicine, a domestic central laboratory recently acquired. FRONTAGE's core overseas laboratory business, valued at $470 million, will ultimately go to CRL. The remaining overseas laboratories, valued at $84.4 million, will be distributed to Li Song's team.

Tigermed stated that there are significant differences between the company's clinical CRO business and FRONTAGE's laboratory business in terms of business models and resource investment. Through this transaction, the company can divest its overseas laboratory business and focus more on its core clinical CRO operations, which is conducive to optimizing resource allocation.

**Did the Original One-Stop Service Plan Fall Short of Expectations?**

It is understood that FRONTAGE's laboratory business mainly consists of two parts: preclinical laboratories, also known as preclinical CRO, and clinical supporting central laboratories. The preclinical CRO segment complements Tigermed's business within the industry chain, while the clinical supporting central laboratories provide support for Tigermed's main CRO operations.

Notably, when acquiring FRONTAGE over a decade ago, Tigermed's rationale was precisely the complementary role FRONTAGE's business played in its clinical CRO operations.

Looking back at the history between Tigermed and FRONTAGE, in 2014, Tigermed's Hong Kong subsidiary acquired Frontage Labs for $50.25 million. In early 2018, following the restructuring of Frontage Labs, FRONTAGE Holdings listed on the Hong Kong Stock Exchange as the listing entity via a Cayman Islands holding platform.

According to the "Report on Major Asset Acquisition (Revised Draft)" disclosed by Tigermed in 2014, FRONTAGE's main business areas at the time covered preclinical research, early-stage clinical research, and part of late-stage clinical research. Its bioanalysis and CMC pharmaceutical product development capabilities could serve the entire drug development process.

At the time, Tigermed stated that the acquisition would allow Frontage Labs and the listed company to effectively complement each other in the CRO business sector, filling and expanding the listed company's current industrial service chain. Furthermore, by leveraging synergies, the company aimed to create a one-stop CRO service for the listed entity, thereby enhancing its profitability.

Judging by the valuations of the various business segments mentioned above, the retained domestic business, valued at $205.5 million, is significantly smaller than the overseas portion valued at $470 million, indicating that it was not FRONTAGE's primary business. Despite retaining this domestic segment, the majority of the assets were chosen for sale.

Does this imply that the company's original expectation of a one-stop CRO service did not meet expectations during the integration process over the past decade? What considerations lie behind the renewed focus on the core clinical CRO business? Regarding these questions, Caiwen contacted Tigermed's Board Secretary, but no response had been received by the time of publication.

**Exchanging Control for Cash and One-Time Gains**

In terms of short-term gains and losses, according to the announcement, the transaction will generate investment income for Tigermed. The impact on profit is expected to account for more than 50% of the audited net profit of the most recent fiscal year, with an absolute amount exceeding RMB 5 million. Additionally, the company will receive cash consideration.

Tigermed's disclosure indicates that it expects to receive cash consideration of HKD 535,667,400 (equivalent to approximately RMB 461.2 million) corresponding to the cancellation of the 11.09% stake in FRONTAGE directly held by the company during the privatization phase. There will also be cash consideration from subsequent equity adjustments and potential performance bonuses.

Tigermed has already made arrangements for the use of these funds.

The announcement shows that approximately 60% of the proceeds from this transaction are expected to be used for the expansion of the company's overseas business, overseas clinical CRO operations, and potential acquisitions of related targets; 20% is expected to be used for general corporate purposes; and the remaining 20%, after assessment, will be used for dividends or share buybacks to enhance shareholder investment returns.

The cost is that FRONTAGE will no longer be included in Tigermed's consolidation scope. Data from Tonghuashun iFinD shows that FRONTAGE's revenue and net profit attributable to shareholders in 2025 were $257 million and $7 million, respectively, equivalent to approximately RMB 1.795 billion and RMB 48 million. For Tigermed, FRONTAGE's contribution to performance cannot be ignored, especially given that its revenue contribution exceeded 20% during the same period. If it is no longer consolidated, the company may face a corresponding revenue gap.

However, against the backdrop of an overall recovery in the innovative drug sector, Tigermed's performance is also improving.

A recent research report by Dongwu Securities pointed out that, accompanied by the optimization of supply in the clinical CRO industry and the recovery of demand for innovative drug R&D, Tigermed's net new orders have accelerated year-on-year, and the average unit price of newly signed orders has returned to growth, providing support for subsequent recovery in non-recurring net profit. By the end of September, the company's contract liabilities increased to RMB 1.436 billion, a 33.10% increase from the beginning of the year, mainly driven by an increase in advance payments for new orders, further supporting the trend of order improvement translating into revenue.

In the first three quarters of 2026, Tigermed achieved revenue of RMB 5.792 billion, a year-on-year increase of 15.23%; net profit attributable to shareholders after deducting non-recurring items was RMB 450 million, a year-on-year increase of 38.08%, reversing the previous downward trend in non-recurring net profit. However, the company reported a net loss attributable to shareholders of RMB 272 million during the same period, primarily due to significant industrial investments by Tigermed, where substantial drawdowns on the investment side led to losses.

Despite entering a recovery channel, Tigermed still faces pressure from existing orders.

Dongwu Securities noted that existing low-priced orders continue to exert pressure on Tigermed's current profitability. In the first three quarters of 2026, the company's comprehensive gross margin was 27.04%, relatively flat compared to 27.53% in the first half of the year, indicating that the improvement in volume and price of newly signed orders has not yet fully translated into current profitability. The superposition of three factors has resulted in profitability not yet rebounding.

### Related Stocks

- [01521.HK](https://longbridge.com/en/quote/01521.HK.md)
- [03347.HK](https://longbridge.com/en/quote/03347.HK.md)
- [300347.CN](https://longbridge.com/en/quote/300347.CN.md)

## Related News & Research

- [TIGERMED Joins Proposed Privatization of FRONTAGE and Asset Disposal; FRONTAGE Surges 40%+](https://longbridge.com/en/news/304940017.md)
- [Tigermed plans to sell Frontage's overseas laboratory business to Charles River, Song Li](https://longbridge.com/en/news/304988489.md)
- [Hangzhou Tigermed Consulting To Participate In Privatisation Of Unit Frontage](https://longbridge.com/en/news/304851534.md)
- [HK-listed Frontage to be taken private in $616 million deal backed by Charles River](https://longbridge.com/en/news/304851714.md)
- [Charles River agrees $470m deal for Frontage assets](https://longbridge.com/en/news/304995627.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**